Thalidomide controls adipose tissue inflammation associated with high-fat diet-induced obesity in mice

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 15, Issue 2, 2015, Pages 151-158

  Nakamitsu, Patricia Z ^a   Compri, Cecilia M ^a   de Pinto, Livia Fraia ^a   Gotardo, Èrica M F ^a   de Oliveira, Caroline C ^a   Ribeiro, Marcelo L ^a   Pedrazzoli, Josè ^a   Gambero, Alessandra ^a  

^a Universidade Sao Francisco Centro de Ciencias Biologicas e da Saude   (Brazil)

Author keywords

3T3 L1 cells; Adipokines; C Jun N terminal kinase; Immunosuppressant; Macrophage; Obesity

Indexed keywords

ADIPOCYTOKINE; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; LEPTIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; ENZYME IMMUNOASSAY; FAT MASS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPID DIET; MACROPHAGE; MALE; MOUSE; MRNA EXPRESSION ASSAY; NONHUMAN; OBESITY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WHITE ADIPOSE TISSUE; 3T3 CELL LINE; ADIPOGENESIS; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PANNICULITIS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME FACTOR;

3T3-L1 CELLS; ADIPOGENESIS; ADIPOKINES; ADIPOSE TISSUE; ADIPOSITY; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MACROPHAGES; MALE; MICE; OBESITY; PANNICULITIS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THALIDOMIDE; TIME FACTORS;

EID: 84930521279     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530314666141128115225     Document Type: Article

References (27)

1. [1] Mraz, M.; Haluzik, M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J. Endocrinol., 2014, 222(3), R113-R127
2. [2] Jiao, P.; Chen, Q.; Shah, S.; Du, J.; Tao, B.; Tzameli, I.; Yan, W.; Xu, H. Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways. Diabetes, 2009, 58 (1), 104-15.
3. [3] Nishimura, S.; Manabe, I.; Nagasaki, M.; Seo, K.; Yamashita, H.; Hosoya, Y.; Ohsugi, M.; Tobe, K.; Kadowaki, T.; Nagai, R.; Sugiura, S. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J. Clin. Invest., 2008, 118 (2), 710-721.
4. [4] Maury, E.; Brichard, S.M. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell. Endocrinol., 2010, 314(1), 1-16.
5. [5] Hotamisligil, G.S.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance. Science, 1993, 259(5091), 87-91.
6. [6] Tarantino, G. Gut microbiome, obesity-related comorbidities, and low-grade chronic inflammation. J. Clin. Endocrinol. Metab., 2014, 99(7), 2343-2346.
7. [7] Hartono, C.; Muthukumar, T.; Suthanthiran, M. Immunosuppressive drug therapy. Cold Spring Harb. Perspect. Med., 2013, 3(9), a015487
8. Zenlea, T.; Peppercorn, M.A., Immunosuppressive therapies for inflammatory bowel disease. World Journal of Gastroenterology: WJG, 2014, 20(12), 3146-3152.
9. [8] Araujo, E.P.; De Souza, C.T.; Ueno, M.; Cintra, D.E.; Bertolo, M. B.; Carvalheira, J.B.; Saad, M.J.; Velloso, L.A. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology, 2007, 148(12), 5991-5997.
10. [9] Barbuio, R.; Milanski, M.; Bertolo, M.B.; Saad, M.J.; Velloso, L. A. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J. Endocrinol., 2007, 194(3), 539-550.
11. [10] Chan, E.S.; Cronstein, B.N. Mechanisms of action of methotrexate. Bull. Hosp. Jt. Dis., 2013, 71(Suppl 1), S5-S8.
12. [11] DeOliveira, C.C.; Acedo, S.C.; Gotardo, E.M.; Carvalho Pde, O.; Rocha, T.; Pedrazzoli, J., Jr.; Gambero, A. Effects of methotrexate on inflammatory alterations induced by obesity: an in vivo and in vitro study. Mol. Cell. Endocrinol., 2012, 361(1-2), 92-98.
13. [12] Azzi, J.R.; Sayegh, M. H.; Mallat, S. G. Calcineurin inhibitors: 40 years later, can't live without. J. Immunol., 2013, 191(12), 5785-91.
14. [13] Jiang, M.; Wang, C.; Meng, Q.; Li, F.; Li, K.; Luo, L.; Sun, C. Cyclosporin A attenuates weight gain and improves glucose tolerance in diet-induced obese mice. Mol. Cell. Endocrinol., 2013, 370(1-2), 96-102.
15. [14] Horton, M.R.; Hallowell, R.W. Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. Drugs Today, 2012, 48(10), 661-71.
16. [15] Rupnick, M.A.; Panigrahy, D.; Zhang, C.Y.; Dallabrida, S.M.; Lowell, B.B.; Langer, R.; Folkman, M.J. Adipose tissue mass can be regulated through the vasculature. Proc. Nat. Acad. Sci. USA, 2002, 99(16), 10730-10735.
17. [16] Zhang, C.; Zhang, X.; Ma, L.; Peng, F.; Huang, J.; Han, H. Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy. Endocrine, 2012, 41(2), 248-255.
18. [17] Pinto, L.D.; Compri, C.M.; Fornari, J.V.; Bartchewsky, W.; Cintra, D.E.; Trevisan, M.; Carvalho, P.D.; Ribeiro, M.L.; Velloso, L.A.; Saad, M.J.; Pedrazzoli, J.; Gambero, A. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a highfat diet in mice. Liver Int., 2010, 30(4), 603-610.
19. [18] Gregor, M.F.; Hotamisligil, G.S. Inflammatory mechanisms in obesity. Ann. Rev. Immunol., 2011, 29, 415-45.
20. [19] Ursini, F.; Naty, S.; Grembiale, R.D. Infliximab and insulin resistance. Autoimmun. Rev., 2010, 9(8), 536-539.
21. [20] Chang, X.B.; Stewart, A.K. What is the functional role of the thalidomide binding protein cereblon? Int. J. Biochem. Mol. Biol., 2011, 2(3), 287-294.
22. [21] Coughlan, K.A.; Valentine, R.J.; Ruderman, N.B.; Saha, A.K. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab. Syndr. Obes., 2014, 7, 241-53.
23. [22] Li, Y.; Jiang, Z.; Xiao, Y.; Li, L.; Gao, Y. Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro. Hematol. Oncol., 2012, 30(1), 13-21
24. [23] Moreira, A.L.; Sampaio, E.P.; Zmuidzinas, A.; Frindt, P.; Smith, K. A.; Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med., 1993, 177(6), 1675-1680;
25. Paul, S.C.; Lv, P.; Xiao, Y.J.; An, P.; Liu, S.Q.; Luo, H.S. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB. Pathobiology, 2006, 73(2), 82-92.
26. [24] Kamei, N.; Tobe, K.; Suzuki, R.; Ohsugi, M.; Watanabe, T.; Kubota, N.; Ohtsuka-Kowatari, N.; Kumagai, K.; Sakamoto, K.; Kobayashi, M.; Yamauchi, T.; Ueki, K.; Oishi, Y.; Nishimura, S.; Manabe, I.; Hashimoto, H.; Ohnishi, Y.; Ogata, H.; Tokuyama, K.; Tsunoda, M.; Ide, T.; Murakami, K.; Nagai, R.; Kadowaki, T. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem., 2006, 281(36), 26602-26614.
27. [25] Takahashi, K.; Yamaguchi, S.; Shimoyama, T.; Seki, H.; Miyokawa, K.; Katsuta, H.; Tanaka, T.; Yoshimoto, K.; Ohno, H.; Nagamatsu, S.; Ishida, H. JNK-and IkappaB-dependent pathways regulate MCP-1 but not adiponectin release from artificially hypertrophied 3T3-L1 adipocytes preloaded with palmitate in vitro. Am. J. Physiol. Endocrinol. Metab., 2008, 294(5), E898-E909